MoonLake Immunotherapeutics (MLTX) has become a focus for many investors after strong one-year Phase 3 VELA data for sonelokimab in hidradenitis suppurativa and a planned Biologics License Application filing by the end of September.

That clinical update has come alongside a sharp move in MoonLake Immunotherapeutics’ share price, with a 7-day share price return of 11.80% and a 30-day share price return of 16.66%. However, the 1-year total shareholder return remains down 53.63%, pointing to improving short-term momentum against a weak recent track record.

If Sonelokimab’s data has you looking more closely at healthcare-focused opportunities, it could be a good time to widen your search using our screener for 38 healthcare AI stocks

With MoonLake Immunotherapeutics now trading at $21.22, only around 30% below the average analyst price target of $27.62, the key question is whether recent clinical success and the $200m equity raise leave meaningful upside, or if the stock is already pricing in future growth.

Preferred Price-to-Book Multiple of 6.1x: Is It Justified?

With MoonLake Immunotherapeutics trading on a P/B of 6.1x against a last close of $21.22, the stock currently carries a richer valuation than many peers in the same space.

The price to book ratio compares the company’s market value to its net assets on the balance sheet. This can be a common yardstick for early stage or unprofitable biotechs where earnings are not yet a guide. For MoonLake Immunotherapeutics, the current 6.1x P/B suggests investors are paying a sizeable premium to the company’s book value despite it being unprofitable and forecast to remain unprofitable over the next 3 years.

Relative to the US Biotechs industry average P/B of 2.6x, MoonLake Immunotherapeutics is valued at more than double on this metric. It is also described as expensive versus a 5.2x peer average. That sets a high bar for future progress, as the current price already reflects a stronger outlook than is implied for many other biotechs trading on lower multiples.

Result: Price-to-book of 6.1x (OVERVALUED)

However, MoonLake Immunotherapeutics still carries clear risks, including ongoing losses of $257.081 million and reliance on successful execution of planned regulatory milestones for sonelokimab.

Next Steps

Given both the recent pressure on MoonLake Immunotherapeutics’ share price and the clinical progress, it makes sense to act quickly and review the full picture yourself. To see how the trade off between potential rewards and flagged risks stacks up in detail, start with the 1 key reward and 4 important warning signs.

Looking for more investment ideas beyond MoonLake Immunotherapeutics?

If you are watching MoonLake Immunotherapeutics closely, do not limit your watchlist. The next compelling opportunity might already fit your style if you scan widely.

• Target resilient income by reviewing companies in the 7 dividend fortresses that could complement a growth focused position like MoonLake Immunotherapeutics.
• Spot potential mispriced opportunities by checking the 44 high quality undervalued stocks before the market pays closer attention to their fundamentals.
• Secure more sleep at night by assessing companies in the 67 resilient stocks with low risk scores that may balance out higher risk biotech exposure.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.